Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.
I agree, it was all about me me me and not much about the company going forward. dhlindy: How many people routinely come on here and look to see if a new RNS has been released and then have 2 more clicks to get it when they could just read it straight off if I post it?
Eden Research plc (AIM: EDEN), the AIM-listed company that develops and supplies breakthrough biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries, will hold its AGM today at 1.30pm at the Institute of Directors, 116 Pall Mall, London SW1Y 5ED. At the meeting Eden's Chairman, Lykele van der Broek, will make the following statement: "I am delighted to be Chairing my first AGM for Eden at such an exciting time in the Company's evolution. Since retiring from Bayer CropScience, I have sought out just a few companies in which I could take an interest in and spend time challenging and supporting the executive team to grow and develop their businesses using my experience, and so I was pleased to be offered the role of Chairman at Eden as, after careful consideration, I felt that this business had a lot of potential as well as synergy with my professional background. It seems to me that Eden has invested a significant amount of time and resource to get to where it has got to today and that this is now starting to pay off with commercialisation in full-swing. In short order, we will see crop protection, animal health and consumer products on the market, all of which have been either developed by Eden itself, or by partners using Eden's terpene and SustaineÔ encapsulation technologies. Sustaine clearly has such a wide-variety of applications, which is excellent, however, I think the approach being taken by the Company to concentrate its efforts on a handful of different market sectors, initially, is sensible. Over the coming year, I hope to oversee an increase in revenue along with an increase in research and development activity which will help to advance the Company's product pipeline apace. In addition, I will assist management in expanding the core team so as to effectively manage the increase in activities that we are seeing, as well as using my experience to progress commercial activity, as appropriate. In the longer term, I will strive to help Eden become a significant player in the crop protection, animal health and consumer products sectors, which I believe it can be." Company presentation After the conclusion of the formal business of the AGM, Eden's Chief Executive Officer will provide a short presentation to investors with an overview of Company progress and strategy. No new material information will be disclosed in the presentation and it will be available on the Company's website later today.
Eden Research plc (AIM: EDEN), the AIM listed company that develops and supplies breakthrough biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries, announces that Sean Smith, CEO, has purchased 213,921 ordinary shares of 1p each in Eden ("Ordinary Shares") at a price of £0.14. Following the transaction outlined above, Mr Smith's interest in the share capital of the Company is 213,921 Ordinary Shares, representing 0.10 per cent of the Company's issued share capital.
#nothinghappensquicklyinedensworld Eden Research plc (AIM: EDEN), the AIM listed company that develops and supplies breakthrough biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries, announces that the United States Environmental Protection Agency ("EPA") has commenced its scientific review of Eden's two formulated products and three active ingredients as pesticides for use in the United States. The scientific reviews are expected to be complete before the end of 2019. Eden's applications cover its first two products and their respective active ingredients: Mevalone™, Eden's fungicide for the treatment of botrytis on grapes and a range of other crops, and Cedroz™, a nematicide product for farmers that controls a wide range of economically important nematodes and that is being commercialised in 29 countries by Eden's partner Eastman. Mevalone is currently approved in ten countries, including the top three wine producing countries in the world. The United States ("US") is the fourth largest wine producing country and the third largest vine fungicide market in the world behind Italy and France. Mevalone is marketed under several trade names by Eden's partners SumiAgro (France), Sipcam (Italy and Spain), Efthymidis (Greece, Portugal and the Balkans) and Lachlan (Kenya). Discussions are currently underway regarding the appointment of appropriate distribution partners for Mevalone in the US. Cedroz is an innovative formulation based on specific nature-identical terpenes and an encapsulation technology which was developed and patented by Eden Research plc ("Eden"). Eastman is Eden's exclusive partner for the development and distribution of this product in more than 25 key countries around the world. The favourable toxicological regulatory profile of Cedroz will provide a high level of flexibility on the timing of application for farmers and comfort for workers. In all regulatory trials completed, no terpene residues were found in the crops at harvest. Sean Smith, Chief Executive Officer of Eden, said: "Following the successful execution of partnership agreements with Eastman and Sipcam over the past eighteen months and the successful fund raising associated with Sipcam's investment in Eden, we are now actively pursuing the expansion of our portfolio of regulatory approvals in order to fully realise the value of our technology and products. This is integral to our commercial success given the importance of these approvals to the commercialisation of crop protection products."
Looks like a long time till any dividends are given. It looks to me that future income for quite a while will go into R&D. Canny salary for Smith - �147,000 + 61% of that bonus. I can see revenue of �1.9mn but how much of that is product sales?
Eden Research plc (AIM: EDEN), the AIM listed company that provides breakthrough natural microencapsulation technologies to the global crop protection, animal health and consumer products industries, announces that its Annual Report and Accounts for the year ended 31 December 2017, Notice of the Annual General Meeting ("AGM") and a Form of Proxy have been posted to shareholders and are now available on the Company's website: www.edenresearch.com The AGM is to be held on Thursday 21 June 2018 at 1.30pm at the Institute of Directors, 116 Pall Mall, London SW1Y 5ED.
Well said, 2017. How can they hope to succeed when no-one knows they exist? Meanwhile on Twitter today they retweeted Antoine Meyer (SumiAgro): (Google Translate - why can't Eden do that???): Thunderstorms in the #vines touched by # hail in Gironde and Charentes! To help farmers, @SumiAgroFrance recommends the application of #kelpak, based on South African giant algae, to promote the restart of the vine. It works! Try and see for yourself!